Theralase to host conference call Nov. 19

Ms. Kristina Hachey reports THERALASE(R) INVESTOR CONFERENCE CALL REMINDER Theralase Technologies Inc. will host a conference call on Wednesday, Nov. 19, at 11 a.m. ET to provide an update on the company's continuing phase II clinical study for patients diagnosed with Bacillus Calmette-Guerin-(BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ (CIS) (study II), along with a review of financial and operational results for the fiscal quarter ended Sept. 30, 2025. Participants are encouraged to submit questions in advance to [email protected] to ensure sufficient time for discussion. Conference call in:  1-647-558-0588 (Canada)/1-646-558-8656 (United States) -- not required for those attending by Zoom An archived version will be available on the website following the conference call. Study II update As of Nov. 7, 2025: 88 patients have been treated with the primary study procedure, representing 97.8 per cent of the targeted enrolment of 90 patients; 72 patients have completed the clinical study, having been assessed at all required visits or removed by the principal investigator for lack of response; 16 patients remain pending study completion. Interim clinical results demonstrate: 64.3 per cent (54/84) of patients achieved a complete response (CR) at any point in time; 72.6 per cent (61/84) achieved a total response (TR equals CR plus indeterminate response (IR)); At the 450-day assessment; 40 per cent (18/45) of patients maintained a CR; 42.2 per cent (19/45) maintained a TR, demonstrating durability of response. Theralase remains on track to complete enrollment in Q4 2025, with data lock and regulatory submissions expected in Q1 2027. Financial update: Theralase has released its unaudited, condensed, consolidated, interim Q3 2025 financial statements for the period ended Sept. 30, 2025. Financial highlights -- nine months ended Sept. 30, 2025 versus 2024: Revenue decreased 5 per cent to $590,573 from $622,984; Cost of sales decreased 10 per cent to $299,743 (51 per cent of revenue); Gross margin remained stable at $290,830 (49 per cent of revenue); Selling expenses decreased 18 per cent to $212,421; Administrative expenses increased 12 per cent to $1,444,687; Research and development expenses increased 1 per cent to $2,116,540, reflecting increased activity to support study II progress; Net loss increased 3 per cent to $3,435,145, including $708,521 in non-cash expenses such as amortization and stock-based compensation. Operational highlights: $672,627 raised via non-brokered private placement (July 28, 2025); Warrant extensions completed Aug. 29, 2025; $280,000 in outstanding short-term loans as of Novr 7, 2025, at 15-per-cent interest; The company continues to evaluate equity and non-dilutive funding opportunities to support clinical and commercial milestones. For additional information, please refer to the company's management's discussion and analysis (MD&A) available at SEDAR+. About Ruvidar Ruvidar (TLD-1433) is a small molecule, able to be activated by light, radiation, sound and other drugs, intended for the safe and effective destruction of cancer, bacteria and viruses. About Theralase Technologies Inc. Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound, and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of cancer, bacteria and viruses, with minimal impact on surrounding healthy tissue. We seek Safe Harbor.